Dr. Brian Wood reviews the combination antiretroviral medication bictegravir-tenofovir alafenamide-emtricitabine and highlights key clinical trial data, indications, potential side effects, and drug resistance. For more videos visit the National HIV Curriculum website: hiv.uw.edu/mini-lectures.
0:00 Intro
0:18 Bictegravir-Tenofovir alafenamide-Emtricitabine
0:39 INSTIs
1:27 NRTIs
1:54 Clinical Reminders
3:40 Inhibition of Tubular Secretion of Creatinine
4:27 Key Studies
4:46 GS-380-1489 Week 48 Results
6:48 GS-380-1490 Week 48 Results
8:29 GS-380-1878
9:38 GS-380-1878 Results
10:12 BRAAVE2020
11:14 BRAAVE2020 Results
12:04 Resistance
13:53 Weight Change
16:06 Summary
Негізгі бет Mini-Lecture Series: Bictegravir-Tenofovir alafenamide-Emtricitabine
Пікірлер: 15